Interferon Regulatory Factor 1 Binding to p300 Stimulates DNA-Dependent Acetylation of p53

REFERENCES

• Appella, E., and Anderson C. W.. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764–2772.
   PubMedGoogle Scholar
• Barlev, N. A., Liu L., Chehab N. H., Mansfield K., Harris K. G., Halazonetis T. D., and Berger S. L.. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8:1243–1254.
   PubMed Web of Science ®Google Scholar
• Boultwood, J., Fidler C., Lewis S., MacCarthy A., Sheridan H., Kelly S., Oscier D., Buckle V. J., and Wainscoat J. S.. 1993. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. Blood 82:2611–2616.
   PubMed Web of Science ®Google Scholar
• Burysek, L., Yeow W. S., Lubyova B., Kellum M., Schafer S. L., Huang Y. Q., and Pitha P. M.. 1999. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J. Virol. 73:7334–7342.
   PubMed Web of Science ®Google Scholar
• Caspari, T. 2000. How to activate p53. Curr. Biol. 10:R315–R317.
   PubMed Web of Science ®Google Scholar
• Craig, A., Scott M., Burch L., Smith G., Ball K., and Hupp T.. 2003. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep. 4:787–792.
   PubMedGoogle Scholar
• Craig, A. L., Burch L., Vojtesek B., Mikutowska J., Thompson A., and Hupp T. R.. 1999. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 342:133–141.
   PubMedGoogle Scholar
• Dornan, D., and Hupp T. R.. 2001. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep. 2:139–144.
   PubMedGoogle Scholar
• Dornan, D., Shimizu H., Perkins N. D., and Hupp T. R.. 2003. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 278:13431–13441.
   PubMedGoogle Scholar
• Dornan, D., Shimizu H., Burch L., Smith A. J., and Hupp T. R.. 2003. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell Biol. 23:8846–8861.
   PubMedGoogle Scholar
• Espinosa, J. M., and Emerson B. M.. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8:57–69.
   PubMed Web of Science ®Google Scholar
• Gu, W., and Roeder R. G.. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606.
   PubMed Web of Science ®Google Scholar
• Hupp, T. R., and Lane D. P.. 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:865–875.
   PubMedGoogle Scholar
• Hupp, T. R., Lane D. P., and Ball K. L.. 2000. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J. 352:1–17.
   PubMed Web of Science ®Google Scholar
• Iyer, N. G., Chin S. F., Ozdag H., Daigo Y., Hu D. E., Cariati M., Brindle K., Aparicio S., Caldas C., et al. 2004. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc. Natl. Acad. Sci. USA 101:7386–7391.
   PubMed Web of Science ®Google Scholar
• Kirchhoff, S., and Hauser H.. 1999. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Oncogene 18:3725–3736.
   PubMedGoogle Scholar
• Kroger, A., Koster M., Schroeder K., Hauser H., and Mueller P. P.. 2002. Activities of IRF-1. J. Interferon Cytokine Res. 22:5–14.
   PubMedGoogle Scholar
• Lane, D. P., and Hupp T. R.. 2003. Drug discovery and p53. Drug Discov. Today 8:347–355.
   PubMedGoogle Scholar
• Matsuyama, T., Kimura T., Kitagawa M., Pfeffer K., Kawakami T., Watanabe N., Kundig T. M., Amakawa R., Kishihara K., Wakeham A., et al. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75:83–97.
   PubMed Web of Science ®Google Scholar
• Merika, M., Williams A. J., Chen G., Collins T., and Thanos D.. 1998. Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol. Cell 1:277–287.
   PubMed Web of Science ®Google Scholar
• Nozawa, H., Oda E., Nakao K., Ishihara M., Ueda S., Yokochi T., Ogasawara K., Nakatsuru Y., Shimizu S., Ohira Y., Hioki K., Aizawa S., Ishikawa T., Katsuki M., Muto T., Taniguchi T., and Tanaka N.. 1999. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 13:1240–1245.
   PubMed Web of Science ®Google Scholar
• Ogasawara, S., Tamura G., Maesawa C., Suzuki Y., Ishida K., Satoh N., Uesugi N., Saito K., and Satodate R.. 1996. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 110:52–57.
   PubMedGoogle Scholar
• Oren, M. 2003. Decision making by p53: life, death and cancer. Cell Death Differ. 10:431–442.
   PubMed Web of Science ®Google Scholar
• Orlando, V., Strutt H., and Paro R.. 1997. Analysis of chromatin structure by in vivo formaldehyde cross-linking. Methods 11:205–214.
   PubMed Web of Science ®Google Scholar
• Pamment, J., Ramsay E., Kelleher M., Dornan D., and Ball K. L.. 2002. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21:7776–7785.
   PubMed Web of Science ®Google Scholar
• Prost, S., Bellamy C. O., Cunningham D. S., and Harrison D. J.. 1998. Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes. FASEB J. 12:181–188.
   PubMedGoogle Scholar
• Sakaguchi, K., Herrera J. E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C. W., and Appella E.. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841.
   PubMed Web of Science ®Google Scholar
• Schon, O., Friedler A., Bycroft M., Freund S. M., and Fersht A. R.. 2002. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323:491–501.
   PubMed Web of Science ®Google Scholar
• Seo, T., Park J., Lee D., Hwang S. G., and Choe J.. 2001. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J. Virol. 75:6193–6198.
   PubMed Web of Science ®Google Scholar
• Shieh, S. Y., Ahn J., Tamai K., Taya Y., and Prives C.. 2000. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:289–300.
   PubMed Web of Science ®Google Scholar
• Shikama, N., Lee C. W., France S., Delavaine L., Lyon J., Krstic-Demonacos M., and La Thangue N. B.. 1999. A novel cofactor for p300 that regulates the p53 response. Mol. Cell 4:365–376.
   PubMed Web of Science ®Google Scholar
• Stevens, A. M., and Yu-Lee L. Y.. 1994. Multiple prolactin-responsive elements mediate G1 and S phase expression of the interferon regulatory factor-1 gene. Mol. Endocrinol. 8:345–355.
   PubMedGoogle Scholar
• Tamura, G., Ogasawara S., Nishizuka S., Sakata K., Maesawa C., Suzuki Y., Terashima M., Saito K., and Satodate R.. 1996. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res. 56:612–615.
   PubMed Web of Science ®Google Scholar
• Tamura, T., Ishihara M., Lamphier M. S., Tanaka N., Oishi I., Aizawa S., Matsuyama T., Mak T. W., Taki S., and Taniguchi T.. 1995. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376:596–599.
   PubMed Web of Science ®Google Scholar
• Tanaka, N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M. S., Aizawa S., Mak T. W., and Taniguchi T.. 1994. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77:829–839.
   PubMed Web of Science ®Google Scholar
• Tanaka, N., Ishihara M., Lamphier M. S., Nozawa H., Matsuyama T., Mak T. W., Aizawa S., Tokino T., Oren M., and Taniguchi T.. 1996. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 382:816–818.
   PubMed Web of Science ®Google Scholar
• Taniguchi, T., and Takaoka A.. 2002. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 14:111–116.
   PubMed Web of Science ®Google Scholar
• Wahl, G. M., and Carr A. M.. 2001. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell Biol. 3:E277–E286.
   PubMed Web of Science ®Google Scholar
• Willman, C. L., Sever C. E., Pallavicini M. G., Harada H., Tanaka N., Slovak M. L., Yamamoto H., Harada K., Meeker T. C., List A. F., et al. 1993. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259:968–971.
   PubMed Web of Science ®Google Scholar
• Yuan, Z. M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Shioya H., Utsugisawa Y., Yokoyama K., Weichselbaum R., Shi Y., and Kufe D.. 1999. Role for p300 in stabilization of p53 in the response to DNA damage. J. Biol. Chem. 274:1883–1886.
   PubMedGoogle Scholar